Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/127263
Title: Identification of six new susceptibility loci for invasive epithelial ovarian cancer
Author: Kuchenbaecker, Karoline B.
Ramus, Susan J.
Tyrer, Jonathan P.
Lee, Andrew
Shen, Howard C.
Beesley, Jonathan
Lawrenson, Kate
McGuffog, Lesley
Healey, Sue
Lee, Janet M.
Spindler, Tassja J.
Lin, Yvonne G.
Pejovic, Tanja
Bean, Yukie
Li, Qiyuan
Coetzee, Simon
Hazelett, Dennis
Miron, Alexander
Southey, Melissa C.
Terry, Mary Beth
Goldgar, David E.
Buys, Saundra S.
Janavicius, Ramunas
Dorfling, Cecilia M.
van Rensburg, Elizabeth J.
Neuhausen, Susan L.
Ding, Yuan Chun
Hansen, Thomas V. O.
Jønson, Lars
Gerdes, Anne Marie
Ejlertsen, Bent
Barrowdale, Daniel
Dennis, Joe
Benitez, Javier
Osorio, Ana
Garcia, Maria Jose
Komenaka, Ian
Blanco Guillermo, Ignacio
Lázaro García, Conxi
Pujana Genestar, M. Ángel
Keywords: Genoma humà
Genètica del desenvolupament
Cèl·lules epitelials
Càncer d'ovari
Nucleòtids
Human genome
Developmental genetics
Epithelial cells
Ovarian cancer
Nucleotides
Issue Date: Feb-2015
Publisher: Nature Publishing Group
Abstract: Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 and BRCA2 mutation carriers who are at high risk of EOC. After imputation to 1000 Genomes Project data, we assessed associations of 11 million genetic variants with EOC risk from 15,437 cases unselected for family history and 30,845 controls and from 15,252 BRCA1 mutation carriers and 8,211 BRCA2 mutation carriers (3,096 with ovarian cancer), and we combined the results in a meta-analysis. This new study design yielded increased statistical power, leading to the discovery of six new EOC susceptibility loci. Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 × 10(-8). Incorporating these variants into risk assessment tools will improve clinical risk predictions for BRCA1 and BRCA2 mutation carriers.
Note: Versió postprint del document publicat a: https://doi.org/10.1038/ng.3185
It is part of: Nature Genetics, 2015, vol. 47, num. 2, p. 164-171
URI: http://hdl.handle.net/2445/127263
Related resource: https://doi.org/10.1038/ng.3185
ISSN: 1061-4036
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
676326.pdf1.22 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.